Younghee Park1, Kyubo Kim2, Hae Jin Park3, Seung-Yong Jeong4, Kyu Joo Park4, Sae-Won Han5, Tae-You Kim5, Eui Kyu Chie6. 1. 1 Department of Radiation Oncology, Soonchunhyang University Seoul Hospital , Seoul , Republic of Korea. 2. 2 Department of Radiation Oncology, Ewha Womans University College of Medicine , Republic of Korea. 3. 3 Department of Radiation Oncology, Hanyang University College of Medicine , Seoul, Republic of Korea. 4. 4 Department of Surgery, Seoul National University College of Medicine , Seoul , Republic of Korea. 5. 5 Department of Internal Medicine, Seoul National University College of Medicine , Seoul , Republic of Korea. 6. 6 Department of Radiation Oncology, Seoul National University College of Medicine , Seoul , Republic of Korea.
Abstract
OBJECTIVE: To evaluate outcomes and toxicity profiles after re-irradiation in patients with pelvic recurrence of anorectal cancer. METHODS: 25 anorectal cancer patients who received re-irradiation for pelvic recurrence between 2005 and 2015 were included. For initial treatment, all patients underwent surgical resection and preoperative or postoperative radiotherapy. RESULTS: The median follow-up duration was 21.5 months (range, 2.9-84.4). After a median of 43.3 months (range, 11.7-218.5), patients received re-irradiation with a median dose of 45 Gy (range, 36-60). The equivalent dose in 2 Gy fractions (EQD2) of re-irradiation-calculated using α/β = 10 Gy-ranged from 34.5 to 84.0 Gy (median, 46.4). Surgical resection was performed for 11 patients, and 14 patients received concurrent chemotherapy with re-irradiation. The 3-year local progression-free survival was 29.7%. The 3-year overall survival was 49.7%. Concurrent chemotherapy with re-irradiation and re-irradiation doses >50 Gy EQD2α/β=10 were significant prognostic factors for local progression free survival and overall survival according to multivariate analysis. 90% (9 of 10) of patients with symptoms had improvement after re-irradiation. Among 23 patients available for evaluation of late toxicity, 12 developed late toxicities. There were no Grade 4 late toxicities, and 6 patients had Grade 3 late toxicities (small bowel obstruction, bowel perforation and fistula). CONCLUSION: Re-irradiation for pelvic recurrence of anorectal cancer improved symptoms of patients but the rate of late toxicity was high. Further investigation for patient selection is required. ADVANCES IN KNOWLEDGE: Re-irradiation could be considered as a possible option for pelvic recurrence of anorectal cancer in selected patients.
OBJECTIVE: To evaluate outcomes and toxicity profiles after re-irradiation in patients with pelvic recurrence of anorectal cancer. METHODS: 25 anorectal cancer patients who received re-irradiation for pelvic recurrence between 2005 and 2015 were included. For initial treatment, all patients underwent surgical resection and preoperative or postoperative radiotherapy. RESULTS: The median follow-up duration was 21.5 months (range, 2.9-84.4). After a median of 43.3 months (range, 11.7-218.5), patients received re-irradiation with a median dose of 45 Gy (range, 36-60). The equivalent dose in 2 Gy fractions (EQD2) of re-irradiation-calculated using α/β = 10 Gy-ranged from 34.5 to 84.0 Gy (median, 46.4). Surgical resection was performed for 11 patients, and 14 patients received concurrent chemotherapy with re-irradiation. The 3-year local progression-free survival was 29.7%. The 3-year overall survival was 49.7%. Concurrent chemotherapy with re-irradiation and re-irradiation doses >50 Gy EQD2α/β=10 were significant prognostic factors for local progression free survival and overall survival according to multivariate analysis. 90% (9 of 10) of patients with symptoms had improvement after re-irradiation. Among 23 patients available for evaluation of late toxicity, 12 developed late toxicities. There were no Grade 4 late toxicities, and 6 patients had Grade 3 late toxicities (small bowel obstruction, bowel perforation and fistula). CONCLUSION: Re-irradiation for pelvic recurrence of anorectal cancer improved symptoms of patients but the rate of late toxicity was high. Further investigation for patient selection is required. ADVANCES IN KNOWLEDGE: Re-irradiation could be considered as a possible option for pelvic recurrence of anorectal cancer in selected patients.
Authors: Vincenzo Valentini; Alessio G Morganti; M Antonietta Gambacorta; Mohammed Mohiuddin; G Battista Doglietto; Claudio Coco; Antonino De Paoli; Carlo Rossi; Annamaria Di Russo; Francesca Valvo; Giampaolo Bolzicco; Maurizio Dalla Palma Journal: Int J Radiat Oncol Biol Phys Date: 2006-01-18 Impact factor: 7.038
Authors: Randa Tao; Chiaojung Jillian Tsai; Garrett Jensen; Cathy Eng; Scott Kopetz; Michael J Overman; John M Skibber; Miguel Rodriguez-Bigas; George J Chang; Yi-Qian Nancy You; Brian K Bednarski; Bruce D Minsky; Marc E Delclos; Eugene Koay; Sunil Krishnan; Christopher H Crane; Prajnan Das Journal: Radiother Oncol Date: 2017-01-03 Impact factor: 6.280
Authors: Louise Janet Murray; John Lilley; Maria A Hawkins; Ann M Henry; Peter Dickinson; David Sebag-Montefiore Journal: Radiother Oncol Date: 2017-10-21 Impact factor: 6.280
Authors: David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar Journal: Lancet Date: 2009-03-07 Impact factor: 79.321